# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cantor Fitzgerald analyst Charles Duncan maintains Vanda Pharma (NASDAQ:VNDA) with a Overweight and raises the price target ...
Vanda Pharma (NASDAQ:VNDA) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.21) ...
Cantor Fitzgerald analyst Charles Duncan initiates coverage on Vanda Pharma (NASDAQ:VNDA) with a Overweight rating and annou...
Vanda Pharmaceuticals shares decline as Future Pak withdraws acquisition offer following Vanda's rejection and lack of resp...